The Journal of Pain
Volume 9, Issue 6 , Pages 473-486 , June 2008

Nonmedical Use of Prescription Opioids: Motive and Ubiquity Issues

  • James P. Zacny

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Dr. James P. Zacny, Department of Anesthesia and Critical Care, MC4028, The University of Chicago, 5841 S. Maryland Avenue, Chicago, IL 60637.
    • ,
  • Stephanie A. Lichtor

References 

  1. In:  Adlaf EM,  Begin P,  Sawka E editor. Canadian Addiction Survey (CAS): A national survey of Canadians' use of alcohol and other drugs: Prevalence of use and related harms: Detailed report. Ottawa: Canadian Centre on Substance Abuse; 2005;Available at: http://www.ccsa.ca/NR/rdonlyres/6806130B-C314-4C96-95CC-075D14CD83DE/0/ccsa0040282005.pdf Accessed December 6, 2007
  2. Adlaf EM, Paglia-Boak A. (2005) Drug use among Ontario students 1977-2005: detailed OSDUS findings (Centre for Addiction and Mental Health [CAMH], Toronto. Research Document Series No. 16). http://www.camh.net/Research/Areas_of_research/Population_Life_Course_Studies/OSDUS/OSDUS2005_DrugDetailed_final.pdfAccessed December 6, 2007
  3. Australian Institute of Health and Welfare. 2004 National Drug Strategy Household Survey: Detailed Findings (AIHW catno. PHE 66). Canberra: AIHW (Drug Statistics Series No.16); 2005;Available at: http://www.aihw.gov.au/publications/phe/ndshsdf04/ndshsdf04.pdf Accessed December 6, 2007
  4. Ballantyne JC. Opioids for chronic pain: Taking stock. Pain. 2006;125:3–4
  5. Balsa C, Farinha T, Nunes JP, Chaves M: Inquérito nacional ao consumo de substâncias psico-activas na população portuguesa, 2001, CEOS, FCSH-UNL, Lisboa 2003
  6. Bar-Hamburger R, Shufman E. Editorial: Changes in psychoactive drug use in Israel from 1990 until 2001. Isr J Psychiatry Relat Sci. 2002;39:79–82
  7. Beck F, Legleye S, Spilka S, Briffault X, Gautier A, Lamboy B, et al. Drug usage levels in France in 2005: An analysis of the data from the 2005 Health Barometer, relating to psychoactive substances use practices among the adult population (Tendances No. 48, 2005). http://www.ofdt.fr/BDD_len/publications/docs/eftafbm5.pdfaccessed December 6, 2007
  8. Birnbaum HG, White AG, Reynolds JL, Greenberg PE, Zhang M, Vallow S, et al. Estimated costs of prescription opioid analgesic abuse in the United States in 2001. Clin J Pain. 2006;22:667–676
  9. Boyd CJ, McCabe SE, Cranford JA, Young A. Adolescents' motivations to abuse prescription medications. Pediatrics. 2006;118:2472–2480
  10. Canadian Community Epidemiology Network on Drug Use (CCENDU). 2002 National Report; Drug trends and the CCENDU network (Canadian Centre on Substance Abuse [CCSA], 2003). http://www.ccsa.ca/NR/rdonlyres/2982EC4F-53E3-400E-995C-C1822A0F1941/0/CCENDUNational2002e.pdfAccessed December 6, 2007
  11. CIA – The World Factbook – Word. https://www.cia.gov/library/publications/the-world-factbook/geos/xx.html#GovtAccessed December 6, 2007
  12. Cicero TJ, Adams EH, Geller A, Inciardi JA, Munoz A, Schnoll SH, et al. A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States. Drug Alcohol Depend. 1999;57:7–22
  13. Cicero TJ, Dart RC, Inciardi JA, Woody GE, Schnoll S, Munoz A. The development of a comprehensive risk-management program for prescription opioid analgesics: Researched abuse, diversion and addiction-related surveillance (RADARS). Pain Med. 2007;8:157–170
  14. Cicero TJ, Inciardi JA, Munoz A. Trends in abuse of OxyContin and other opioid analgesics in the United States: 2002-2004. J Pain. 2005;6:662–672
  15. Cocco KM, Carey KB. Psychometric properties of the Drug Abuse Screening Test in psychiatric outpatients. Psychol Assess. 1998;10:408–414
  16. Colliver JD, Kroutil LA, Dai L, Gfroerer JC. Misuse of prescription drugs: Data from the 2002, 2003, and 2004 National Surveys on Drug Use and Health (DHHS Publication No. SMA 06-4192, Analytic Series A-28). Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2006;
  17. Compton WM, Volkow ND. Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend. 2006;83S:S4–S7
  18. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: Concerns and strategies. Drug Alcohol Depend. 2006;81:103–107
  19. Dale O, Klepstad P, Kaasa S. The European Union: Not united in opioid use. Palliat Med. 2005;19:177–178
  20. Dasgupta N, Kramer ED, Zalman MA, Carino S, Smith MY, Haddox JD, et al. Association between nonmedical and prescriptive usage of opioids. Drug Alcohol Depend. 2006;82:135–142
  21. Dowling K, Storr CL, Chilcoat HD. Potential influences on initiation and persistence of extramedical prescription pain reliever use in the US population. Clin J Pain. 2006;22:776–783
  22. Eriksen J, Skogren P, Bruera E, Ekholm O, Rasmussen NK. Critical issues on opioids in chronic non-cancer pain: An epidemiological study. Pain. 2006;125:172–179
  23. European Monitoring Centre for Drugs and Drug Addiction. Co-ordination of an expert working group to develop instruments and guidelines to improve quality and comparability of general population surveys on drugs in the EU (Follow up of EMCDDA project CT.96.EP.08 (CT.97.EP.09), Lisbon, EMCDDA). September 1999 http://www.emcdda.europa.eu/index.cfm?fuseaction=public.content&nnodeid=1380&sLanguageiso=ENAccessed December 6, 2007
  24. European Monitoring Centre for Drugs and Drug Addiction. Handbook for surveys on drug use among the general population (EMCDDA project CT.99.EP.08 B, Lisbon, EMCDDA). August 2002 http://www.emcdda.europa.eu/index.cfm?fuseaction=public.content&nnodeid=1380&sLanguageiso=ENAccessed December 6, 2007
  25. European Monitoring Centre for Drugs and Drugs Addiction (EMCDDA). Improving the Comparability of General Population Surveys on Drug Use in the European Union. Lisbon: EMCDDA; 1997;December. Available at: http://www.emcdda.europa.eu/index.cfm?fuseaction=public.content&nnodeid=1380&sLanguageiso=EN Accessed December 6, 2007
  26. European Monitoring Centre for Drugs and Drugs Addiction (EMCDDA). National reports. http://www.emcdda.europa.eu/?nnodeid=435Accessed December 6, 2007
  27. Ewing JA. Detecting alcoholism: The CAGE questionnaire. JAMA. 1984;252:1905–1907
  28. Fischer B, Rehm J, Patra J, Cruz MF. Changes in illicit opioid use across Canada. CMAJ. 2006;175:1385–1387
  29. Fischer UC, Krieger, W: Suchtpräventioun an der Gemeng - Entwicklung, Durchführung und Evaluation eines Modells zur gemeindeorientierten Suchtprävention, CePT, Luxembourg, 1998 (Note: we could not access this article, see footnote in Table 1)
  30. Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain. 2007;8:573–582
  31. French monitoring centre for drugs and drug addiction. Substitution treatments in France: recent results 2004 (Non-substitutive uses of high dosage buprenorphine in France). http://www.ofdt.fr/BDD/publications/docs/eftaack6.pdfp. 12 Accessed December 6, 2007
  32. French MT, Roebuck MC, McGeary KA, Chitwood DD, McCoy CB. Using the Drug Abuse Screening Test (DAST-10) to analyze health services utilization and cost for substance abusers in a community-based setting. Subst Use Misuse. 2001;36:927–946
  33. Gilson AM, Ryan KM, Joranson DE, Dahl JL. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002. J Pain Symptom Manage. 2004;28:176–188
  34. Grant BF, Moore TC, Shepard J, Kaplan K. National Epidemiological Survey on Alcohol and Related Conditions (NESARC) ([NIH NIAAA-NESARC Web site]). http://niaaa.census.gov/index.htmlAccessed December 6, 2007
  35. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: A rational approach to the treatment of chronic pain. Pain Med. 2005;6:107–112
  36. Hakkarainen P, Metso L. Märkä pilvi ja vuosi 2004 (Wet High and the Year 2004). Yhteiskuntapolitiikka. 2005;70:252–265Available at: http://yp.stakes.fi/NR/rdonlyres/C8B86A00-38BC-4023-ADA5-F3A59CEB497F/0/yp32005.pdf, Accessed December 6, 2007 (Note: see footnote in Table 1)
  37. Hartnoll RL. Drug epidemiology in the European institutions: Historical background and key indicators. Bull Narcotics. 2003;55(1-2):53–71
  38. Haydon E, Rehm J, Fischer B, Monga N, Adlaf E. Prescription drug abuse in Canada and the diversion of prescription drugs into the illicit drug market. Can J Public Health. 2005;96:459–461
  39. Health Canada. National thematic workshop on preventing the problematic use of psychotropic pharmaceutics key messages report, 2006. http://www.nationalframework-cadrenational.ca/uploads/files/TWS_PsychoPharma/Pharmaceutical%20Workshop%20Report%20EN.pdfAccessed December 6, 2007
  40. IMG Gallup 2001/ IMG Gallup. Áfengis og vímuvarnará'f0 Íslands. Rannsókn á áfengis- og vímuefnaneyslu Íslendinga. Reykjavík: IMG Gallup. Gallup á Íslandi, 2001. Source accessed from: Kouvonen P, Skretting A, Rosenquist P, eds. Nr 48 Drugs in the Nordic and Baltic countries; common concerns, different realities. 2006 http://www.nad.fi/pdf/48/Chapter%201%2030.1.2006.pdfAccessed December 6, 2007
  41. International Narcotics Control Board. About INCB, Mandate and Functions. http://www.incb.org/incb/mandate.htmlAccessed December 6, 2007
  42. International Narcotics Control Board. Report 2006: Estimated world requirements for 2007: statistics for 2005. Part 4: Statistical information on narcotic drugs. Tables of reported statistics, 2001-2005. New York: United Nations; 2007;Available at: http://www.incb.org/pdf/e/tr/nar/2006/Narcotics_publication_2006_part4_tables.pdf Accessed December 6, 2007
  43. International Narcotics Control Board. Report of the International Narcotics Control Board for 2006. New York: United Nations; 2007;Available at: http://www.incb.org/incb/annual_report_2006.html Accessed December 6, 2007
  44. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future national results on adolescent drug use: Overview of key findings, 2006 ((NIH Publication No. 07-6202)). Bethesda, MD: National Institute on Drug Abuse; 2007;
  45. Joranson DE, Gilson AM. Wanted: A public health approach to prescription opioid abuse and diversion. Pharmacoepidemiol Drug Safety. 2006;15:632–634
  46. Katz NP, Adams EH, Benneyan JC, Birnbaum HG, Budman SH, Buzzeo RW, et al. Foundations of opioid risk management. Clin J Pain. 2007;23:103–118
  47. Korf DJ, Benschop A. Licit and illicit drug use in Malta 2001. University of Amsterdam, 2002 http://www.msp.gov.mt/documents/addictive/licit_illicit_drug_use_malta_2001.pdfAccessed December 6, 2007
  48. Kraus L, Augustin R, Orth B. Illegale Drogen, Einstiegsalter und Trends (Ergebnisse des Epidemiologischen Suchtsurvey 2003). Sucht 51Sonderheft 1S19-S28. 2005;
  49. Maisto SA, Carey MP, Carey KB, Gordon CM, Gleason JR. Use of the AUDIT and the DAST-10 to identify alcohol and drug use disorders among adults with a severe and persistent mental illness. Psychol Assess. 2000;12:186–192
  50. Mayfield D, McLeod G, Hall P. The CAGE questionnaire: Validation of a new alcoholism screening instrument. Am J Psychiat. 1974;131:1121–1123
  51. McCabe SE, Cranford JA, Boyd CJ, Teter CJ. Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addict Behav. 2007;32:562–575
  52. Mounteney J, Leirvåg S-E. Providing an earlier warning of emerging drug trends: The Føre Var system (Drugs: Education, prevention and policy 11:449-471, 2004). http://dx.doi.org/10.1080/09687630412331283527Accessed December 6, 2007
  53. National Advisory Committee on Drugs (NACD)Drug and Alcohol Information and Research Unit (DAIRU). Drug Use in Ireland and Northern Ireland; First Results (Revised) from the 2002-2003 Drug Prevalence Survey - Bulletin 1, 2005. http://www.nacd.ie/publications/Bulletin1_reissue.pdfAccessed December 6, 2007
  54. National Report to the EMCDDA by the Retoix National Focal Point (“Belgium”: New developments, trends, and in-depth information on selected issues, 2006). http://www.emcdda.europa.eu/?nnodeid=435Accessed December 6, 2007
  55. National report (2005 data) to the EMCDDA by the Reitox National Focal Point. Denmark: New developments, trends, and in-depth information on selected issues; 2006;Available at: http://www.emcdda.europa.eu/?nnodeid=435 Accessed December 6, 2007
  56. National Report (2005 data) to the EMCDDA by the Retoix National Focal Point. “Spain”: New developments, trends, and in-depth information on selected issues; 2006;Available at: http://www.emcdda.europa.eu/?nnodeid=435 Accessed December 6, 2007
  57. National report (2004 data) to the EMCDDA by the Reitox National Focal Point. Sweden: New developments, trends, and in-depth information on selected issues; 2005;http://www.emcdda.europa.eu/attachements.cfm/att_22965_EN_Sweden.pdf Accessed December 6, 2007
  58. National report (2005 data) to the EMCDDA by the Reitox National Focal Point. Sweden: new developments, trends, and in-depth information on selected issues; 2006;Available at: http://www.emcdda.europa.eu/?nnodeid=435 Accessed December 6, 2007
  59. Nordlund S. Utviklingen av narkotikabruk I Norge (Drug use in Norway) Nordisk Alkohol- & Narcotikatidskrift 22:197-208, 2005. http://nat.stakes.fi/NR/rdonlyres/D4FE3EF2-627E-427D-B06A-8445A61A799A/0/pdf304.pdfAccessed December 6, 2007
  60. Novak A, Nemeth WC, Lawson KA. Trends in medical use and abuse of sustained-release opioid analgesics: A revisit. Pain Med. 2004;5:59–65
  61. O'Brien S, Black E, Degenhardt L, Roxburgh A, Campbell G, de Graaff B, et al. Australian drug trends 2006: Findings from the Illicit Drug Reporting System (IDRS) NDARC Monograph No. 60, 2006. http://ndarc.med.unsw.edu.au/ndarcweb.nsf/resources/Mono_7/$file/Mono.60.pdfAccessed December 6, 2007
  62. Opioids and Pain European Network of Minds. The White Paper on Opioids and Pain: A Pan-European Challenge. June, 2005 http://www.europeanpainnetwork.com/files/White_Paper.pdfAccessed December 6, 2007
  63. Partanen A, Mäki . Buprenorphine more common as a problem drug in Finland. Nordisk alcohol- and narkotikatidskrift. 2006;21(English supplement):156–161
  64. Passik SD, Heit H, Kirsh KL. Reality and responsibility: A commentary on the treatment of pain and suffering in a drug-using society. J Opioid Manag. 2006;2:123–127
  65. Reid MC, Engles-Horton LL, Weber MB, Kerns RD, Rogers EL, O'Connor PG. Use of opioid medications for chronic noncancer pain syndromes in primary care. J Gen Intern Med. 2002;17:173–179
  66. Relazione Annuale al Parlamento sullo Stato delle Tossicodipendenze in Italia 2006 (Ministero del Lavoro e delle Politiche Sociali, Roma, 2006). http://www.governo.it/GovernoInforma/documenti_ministeri/solidarieta_sociale/relazione_parlamento_2006.pdfAccessed December 6, 2007
  67. Rodenburg G, Spijkerman R, van den Eijnden R, van de Mheen D. Nationaal prevalentie onderzoek middelengebruik. IVO, Rotterdam, Netherlands. 2005 http://www.ivo.nl/upload/downloads/doc_731_Nationaal%20prevalentie%20onderzoek%20middelengebruik%202005.pdfAccessed December 6, 2007
  68. Roe S, Man L. Drug Misuse Declared: Findings from the 2005/06 British Crime Survey, 2006. http://www.homeoffice.gov.uk/rds/pdfs06/hosb1506.pdfAccessed December 6, 2007
  69. Rosenblum A, Parrino M, Schnoll SH, Fong C, Maxwell C, Cleland CM, et al. Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend. 2007;90:64–71
  70. Rösner S, Küfner H. Arzneimittelmissbrauch bei Personen mit Abhängigkeitserkrankungen - Ergebnisse des Monitoring-Systems ebis-med. Suchtmedizin. 2007;9:7–23Available at: http://www.scientificjournals.com/sj/sfp/Abstract/ArtikelId/9260 Accessed December 6, 2007
  71. Schweizerische Fachstelle für Alkohol- und andere Drogenprobleme/Institut suisse de prévention de l'alcoolisme et autres toxicomanies (2004) (Illegale Drogen). http://www.sfa-ispa.ch/DocUpload/d_gebrauch.pdfAccessed December 6, 2007
  72. Skinner H. The Drug Abuse Screening Test. Addict Behav. 1982;7:363–371
  73. Smith MY, Schneider MF, Wentz A, Hughes A, Haddox JD, Dart R. Quantifying morbidity associated with the abuse and misuse of opioid analgesics: A comparison of two approaches. Clin Toxicol (Phila). 2007;45:23–30
  74. Substance Abuse and Mental Health Services AdministrationOffice of Applied Studies. Drug Abuse Warning Network, 2004: National Estimates of Drug-Related Emergency Department Visits ((Office of Applied Studies, DAWN Series D-28, DHHS Publication No. (SMA) 06-4143)). 2006;Rockville, MD
  75. Substance Abuse and Mental Health Services Administration. Results from the 2005 National Survey on Drug Use and Health: National findings ((Office of Applied Studies, NSDUH Series H-302, DHHS Publication No. (SMA) 06-4194)). 2006;Rockville, MD
  76. Substance Abuse and Mental Health Services Administration. Results from the 2006 National Survey on Drug Use and Health: National findings ((Office of Applied Studies, NSDUH Series H-32, DHHS Publication No. (SMA) 07-4293)). 2007;Rockville, MD
  77. Substance Abuse and Mental Health Services Administration. Treatment Episode Data Set (TEDS). Highlights – 2005. National Admissions to Substance Abuse Treatment Services. (Office of Applied Studies, DASIS Series S-36, DHHS Publication No. (SMA) 07-4229). 2006;Rockville, MD
  78. Sung H-E, Richter L, Vaughan R, Johnson PB, Thom B. Nonmedical use of prescription opioids among teenagers in the United States: Trends and correlates. J Adolescent Health. 2005;37:44–51
  79. Uhl A, Springer A, Kobrna U, Gnambs T, Pfarrhofer D. Österreichweite Repräsentativerhebung zu Substanzgrbrauch, Erhebung 2004, Breicht (Wein, Bundesministerium fur Gesundheit und Frauen, 2005). (2005) http://www.praevention.at/upload/documentbox/oesterreichweite_repraesentativerhebung_zu_substanzgebrauch_2004_-_bericht.pdf?PHPSESSID=c1d0d17a1478fa8905e65d9e86b91636Accessed December 6, 2007
  80. United Nations International Drug Control Programme. Global Workshop on Drug Information Systems: Activities, Methods and Future Opportunities, United Nations, 2002. http://www.unodc.org/pdf/gap_global-workshop-report.pdfAccessed December 6, 2007
  81. Wilkins C, Casswell S, Bhatta K, Pledger M. Drug Use in New Zealand: National Surveys Comparison 1998 and 2001, May. Auckland: Alcohol & Public Health Research Unit; 2002;Available at: http://www.aphru.ac.nz/projects/Drugs%20In%20NZ%203.pdf and http://www.aphru.ac.nz/projects/drugs%202001%20Append%203.htm#Appendix%203 Accessed December 6, 2007
  82. Zacny J, Bigelow G, Compton P, Foley K, Iguchi M, Sannerud C. College on Problems of Drug Dependence taskforce on prescription opioid nonmedical use and abuse: Position statement. Drug Alcohol Depend. 2003;69:215–232
  83. Zenz M, Willweber-Strumph A. Opiophobia and cancer pain in Europe. Lancet. 1993;342:1075–1076

 Supported in part by grants DA08573 and DA023969 from the National Institute on Drug Abuse.

 Points of view and opinions expressed by the authors do not necessarily reflect the official position of the National Institute on Drug Abuse.

PII: S1526-5900(08)00348-9

doi: 10.1016/j.jpain.2007.12.008

The Journal of Pain
Volume 9, Issue 6 , Pages 473-486 , June 2008

Article Tools